With the FDA clearance of an investigational new drug application for SynKIR-310, a phase 1 trial evaluating the agent in ...
In an interview with Targeted Oncology for Brain Cancer Awareness Month, Theodore Schwartz, MD, discussed the challenges of ...
During a Case-Based Roundtable® event, Jonathan L. Kaufman, MD, discussed which lines of therapy and at what doses would be ...
Ira Zackon, MD, discusses the results of a real-world study evaluating racial and socioeconomic disparities among patients with chronic lymphocytic leukemia.
Currently, carboplatin or cisplatin with etoposide combined with atezolizumab (Tecentriq) or durvalumab (Imfinzi) followed by ...
Nivolumab with ipilimumab did not lead to progression-free survival benefits in patients with unresectable stage III ...
SNB-101, a nanoparticle drug for small cell lung cancer, received a fast track designation from the FDA for expedited ...
A US health care executive survey found 30% see health equity solely as a social concern. Yet, it's about ensuring everyone has a fair shot at optimal health. Utilizing standardized data can shift ...
The FDA has approved the investigational new drug application of WGc-043, an Epstein-Barr virus-related mRNA cancer vaccine.
IGV-001 is an autologous cell immunotherapy with antisense oligonucleotide targeting IGF-1R. In the phase 1b study, IGV-001 ...
Sima Porten, MD, MPH, discusses the rationale for the phase 3 SunRISe-5 study of TAR-200 in non-muscle invasive bladder ...
During a Case-Based Roundtable® event, Lori A. Leslie, MD, discussed Bruton tyrosine kinase inhibition options for a patient ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results